Engineering antiphagocytic biomimetic drug carriers.
Engineering antiphagocytic biomimetic drug carriers.
复制标题
DOI：
10.4155/tde.13.54
复制
发表时间：
2013-07
影响因子：
4.2
通讯作者：
Peng CA
中科院分区：
文献类型：
--
作者：
Sawdon A;Peng CA
药物输送载体不仅具有治疗许多疾病的潜力，而且还具有诊断多种疾病的潜力；然而，它们仍然缺乏自然颗粒系统的复杂性。使用肿瘤靶向T细胞和肿瘤归巢间充质干细胞的基于细胞的治疗为研究人员提供了一种利用先天生物实体所表现出的特征的方法。同样，病原体的免疫逃避激发了天然聚合物的发展，以掩盖药物载体。CD47蛋白广泛存在于哺乳动物细胞表面，被用来逃避药物载体对吞噬细胞的清除。这篇综述将集中在药物载体利用自然界中的细胞安全地隐藏在人体先天免疫系统雷达下的技巧的最新进展。
Drug-delivery carriers have the potential to not only treat but also diagnose many diseases; however, they still lack the complexity of natural-particulate systems. Cell-based therapies using tumor-targeting T cells and tumor-homing mesenchymal stem cells have given researchers a means to exploit the characteristics exhibited by innate-biological entities. Similarly, immune evasion by pathogens has inspired the development of natural polymers to cloak drug carriers. The ‘marker-of-self’ CD47 protein, which is found ubiquitously on mammalian cell surfaces, has been used for evading phagocyte clearance of drug carriers. This review will focus on the recent progress of drug carriers co-opting the tricks that cells in nature use to hide safely under the radar of the body’s innate immune system.